SPIRONOLACTONE IMPROVES POOR OUTCOME IN PATIENTS WITH NYHA CLASS I OR II CHRONIC HEART FAILURE AND ELEVATED CARDIAC SYMPATHETIC NERVE ACTIVITY

SPIRONOLACTONE IMPROVES POOR OUTCOME IN PATIENTS WITH NYHA CLASS I OR II CHRONIC HEART FAILURE AND ELEVATED CARDIAC SYMPATHETIC NERVE ACTIVITY

Background Mineralocorticoid antagonist has been shown to decrease the morbidity and mortality in patients with systolic chronic heart failure (CHF) and mild symptoms. Since cardiac sympathetic nerve activity (CSNA) is reported to be associated with poor outcome in patients with CHF, we tried to elu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 2012-03, Vol.59 (13), p.E1173-E1173
Hauptverfasser: Kondo, Takumi, Yamada, Takahisa, Morita, Takashi, Furukawa, Yoshio, Tanaka, Koji, Iwasaki, Yusuke, Kawasaki, Masato, Kuramoto, Yuki, Fujimoto, Tadao, Yamamoto, Hironori, Sengoku, Kaoruko, Ozu, Kentaro, Fukunami, Masatake
Format: Artikel
Sprache:eng
Schlagworte:
Cardiology
Cardiovascular
Clinical outcomes
Heart failure
Internal Medicine
Transplants & implants
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Mineralocorticoid antagonist has been shown to decrease the morbidity and mortality in patients with systolic chronic heart failure (CHF) and mild symptoms. Since cardiac sympathetic nerve activity (CSNA) is reported to be associated with poor outcome in patients with CHF, we tried to elucidate the relation between the efficacy of spironolactone and CSNA in CHF patients with NYHA class I or II.
ISSN:0735-1097
1558-3597
DOI:10.1016/S0735-1097(12)61174-7